RYR2 and colorectal carcinoma: To identify druggable genes that can mediate metastasis of this group of patients, we combined bioinformatic analysis, molecular and cell biology and found that RyR2 and its inhibitor S107 possessed the potential to be repurposed to intervene with KRAS mutant CRC metastasis.